Saturday 16 December 2017

Shire to buy Baxalta for $32bn, forging rare diseases leader

The Dublin headquarters of drug-maker Shire Photo: Bloomberg
The Dublin headquarters of drug-maker Shire Photo: Bloomberg

Drugmaker Shire clinched its six-month pursuit of Baxalta International Inc on Monday by agreeing a $32bn cash and stock offer that will make it one of the world's leading rare disease specialists.

The Dublin-based and London-listed group, which first approached the U.S. firm with an all-stock offer in July, won over the maker of treatments for rare blood conditions, cancers and immune system disorders after adding a cash sweetener.

Shareholders will receive $18.00 in cash and 0.1482 Shire American depositary shares per Baxalta share, implying a total value of $45.57 per share based on Jan. 8 prices.

Reuters

Promoted Links

Business Newsletter

Read the leading stories from the world of Business.

Promoted Links

Also in Business